Dark Pharma · DP-033
WE VOTED AT 11:47 A.M. THE FDA APPROVAL WAS FORTY-ONE YEARS OLD. I INITIALLED THE EXECUTIVE SUMMARY.
The Helion Pharmaceuticals board approved a staggering price increase for Parasitrol from $13.50 to $750 per tablet in August 2015, impacting vulnerable patients. CEO Marcus Veld presented the case in merely eighteen minutes, with insufficient discussion on ethical considerations.
Case Assets
The Case Debrief is free to view. Full Case Study, Teaching Notes, Slide Deck, Discussion Guide, and Assessment are available with a Premium subscription.
Brief the Board
PREMIUM
🔒 Unlock
Learn the Case
FREE — included
Study the Case
PREMIUM
🔒 Unlock
Teach the Case
PREMIUM
🔒 Unlock
Present the Case
PREMIUM
🔒 Unlock
Run a Team Discussion
PREMIUM
🔒 Unlock
Test Your Judgement
PREMIUM
🔒 Unlock
Watch the Full Episode
The complete cinematic audio documentary — Dark Pharma
Unlock the Full Case Library
Get every Case Study, Slide Deck, Teaching Notes, Discussion Guide, and Assessment — across a growing library of business cases.
View Pricing →Related Cases
Cases that share a governance or behavioural model with this one.
Dark Pharma
DP-036
SHE RECEIVED THE LIST ON A FRIDAY. LEGAL HAD APPROVED THE LANGUAGE. TH...
Shared: Stakeholder Theory, Ethical Decision-Making Framework
B-School Noir
BN-024
SHE PROPOSED REPLACING THE FLAGSHIP CASE. THE REVIEW COMMITTEE INCLUDE...
Shared: Stakeholder Theory, Ethical Decision-Making Framework
The Raid
HJ-043
The Chairman's Son Fought The Merger In Public. The Vote Came Down To ...
Shared: Stakeholder Theory
Dark Law
DL-037
The Company Sold For Sixty Million Dollars. The Common Shareholders Go...
Shared: Stakeholder Theory